Figure 4From: Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infantsThreshold analysis: group of infants with gestational < 33 weeks.Back to article page